Bioventus (NASDAQ:BVS) Hits New 52-Week High – Still a Buy?

Bioventus Inc. (NASDAQ:BVS) hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $13.85 and last traded at $13.8360, with a volume of 54574 shares changing hands. The stock had previously closed at $13.17.

Analyst Upgrades and Downgrades

BVS has been the topic of several research reports. Barrington Research reissued an “outperform” rating and issued a $14.00 price objective on shares of Bioventus in a research report on Tuesday, June 30th. Weiss Ratings reiterated a “hold (c)” rating on shares of Bioventus in a research note on Tuesday, June 2nd. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $15.00 target price on shares of Bioventus in a report on Tuesday, June 16th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $14.75.

Bioventus Stock Performance

The firm has a market capitalization of $1.16 billion, a PE ratio of 33.70, a price-to-earnings-growth ratio of 1.68 and a beta of 0.63. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.69 and a quick ratio of 1.13. The stock has a 50-day moving average price of $10.30 and a 200-day moving average price of $9.48.

Bioventus (NASDAQ:BVS) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.06. The firm had revenue of $132.09 million during the quarter. Bioventus had a return on equity of 29.97% and a net margin of 4.94%.Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, research analysts expect that Bioventus Inc. will post 0.79 EPS for the current fiscal year.

Hedge Funds Weigh In On Bioventus

Institutional investors and hedge funds have recently made changes to their positions in the business. Bank of America Corp DE grew its position in shares of Bioventus by 40.3% during the first quarter. Bank of America Corp DE now owns 86,057 shares of the company’s stock worth $786,000 after buying an additional 24,723 shares in the last quarter. Engine Capital Management LP acquired a new stake in Bioventus in the first quarter valued at $2,876,000. Quantinno Capital Management LP raised its holdings in Bioventus by 119.6% in the first quarter. Quantinno Capital Management LP now owns 72,023 shares of the company’s stock valued at $658,000 after acquiring an additional 39,222 shares in the last quarter. Lazard Asset Management LLC boosted its stake in Bioventus by 12.9% during the 1st quarter. Lazard Asset Management LLC now owns 305,517 shares of the company’s stock valued at $2,789,000 after acquiring an additional 35,008 shares during the last quarter. Finally, Sei Investments Co. boosted its stake in Bioventus by 160.7% during the 1st quarter. Sei Investments Co. now owns 289,648 shares of the company’s stock valued at $2,644,000 after acquiring an additional 178,539 shares during the last quarter. 62.94% of the stock is currently owned by hedge funds and other institutional investors.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.